ZHIFEI-BIOL(SZ:300122) Zheng Quan Shi Bao Wang·2025-08-13 07:14Core Viewpoint - Zhifei Biological has achieved a significant breakthrough in the influenza vaccine sector with the successful administration of the first dose of its quadrivalent influenza virus split vaccine in Hefei, Anhui Province, marking a milestone in its independent research and development efforts [1][3]. Group 1: Product Development and Market Position - The quadrivalent influenza vaccine is based on virus strains recommended by the World Health Organization and is suitable for individuals aged 3 and above, demonstrating good safety through its production process [3]. - The company has multiple self-developed products in the influenza vaccine field, including a quadrivalent split vaccine for children and a trivalent split vaccine, which are currently under review for market approval [4]. - Zhifei Biological has established three major research and production bases in Beijing, Anhui, and Chongqing, along with an innovation incubation center, enhancing its capabilities in vaccine development and production [3]. Group 2: Research and Development Investment - In 2024, the company plans to invest 1.391 billion yuan in research and development, increasing its R&D personnel to 1,072, with a total R&D investment of nearly 6 billion yuan over the past three years [3]. - The company is focused on addressing national public health needs and has several vaccine products in various stages of development, including clinical trials and market approval processes [4]. Group 3: Global Expansion and Clinical Trials - Zhifei Biological's self-developed products have been exported to dozens of countries, with clinical or registration work ongoing in nearly 20 countries [4]. - The company is advancing multiple new vaccine varieties, including a freeze-dried human rabies vaccine and a 15-valent pneumococcal conjugate vaccine, which are in the market review stage [4].